Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Issuer") priced $1,000.0 million aggregate principal amount of its 8. ...

Shareholders of the Irish drug maker, which has its U.S. base in Hazelwood, and its Pennsylvania-based merger target have ...

DUBLIN and MALVERN, Pa., March 13, 2025/ PRNewswire/-- Mallinckrodt plc and Endo, Inc. today announced that they have entered into a definitive agreement to combine in a stock and cash transaction ...

Mallinckrodt and Endo announced that their respective shareholders have provided the necessary shareholder approvals for the ...

DUBLIN, Ireland & MALVERN, PA — Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have detailed the senior leadership structure for their anticipated merger, a move aimed at creating a global … ...

Overall, 16 suspect lots have been implicated in the latest generic clonazepam pull. The batches in question contain 0.125-mg, 0.25-mg, 1-mg and 2-mg doses of the drug and were shipped out to ...

Clonazepam Orally Disintegrating Tablets, USP 0.125mg, Lot# 550147301, expiration date August 2026. At this time, there have been no reports of adverse reactions related to this recall.

Mallinckrodt PLC, an Irish pharmaceutical company with a big footprint and long history in the St. Louis area, will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion.

Endo, Inc. (OTCQX: NDOI) ("Endo" or the "Company"), a diversified specialty pharmaceutical company transforming insights into life-enhancing therapies, today announced that the U.S. Securities and ...

Endo's initial capital structure is expected to consist of a $400.0 million senior secured five-year super-priority revolving credit facility (undrawn at emergence), a $1,500.0 million senior ...

Offering Part of Endo's $2.5 billion Exit Financing MALVERN, Pa., April 12, 2024 /PRNewswire/ -- Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Anzeige ...